# Phase-3 Study of ASP7374, Cell-culture-derived Influenza Vaccine

> **NCT01767896** · PHASE3 · COMPLETED · sponsor: **UMN Pharma Inc.** · enrollment: 1020 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** ASP7374
- **BIOLOGICAL:** approved egg-derived TIV

## Key facts

- **NCT ID:** NCT01767896
- **Lead sponsor:** UMN Pharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 1020 (ACTUAL)
- **Last updated:** 2017-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01767896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01767896, "Phase-3 Study of ASP7374, Cell-culture-derived Influenza Vaccine". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01767896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*